Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 113 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Factor IX Clear all
Completed No phase listed Observational

LTFU for Gene Transfer Subjects With Hemophilia B

NCT00515710
View directory record Official record
Conditions
Hemophilia B
Interventions
Not listed
Lead sponsor
Spark Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2020 · Synced Oct 19, 2026, 4:43 AM EDT
Withdrawn Phase 3 Interventional

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B

NCT02048111
View directory record Official record
Conditions
Hemophilia B
Interventions
IB1001
Biological
Lead sponsor
Cangene Corporation
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 23, 2016 · Synced Oct 19, 2026, 4:43 AM EDT
Completed Phase 3 Interventional Results available

Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B

NCT01440946
View directory record Official record
Conditions
Hemophilia B
Interventions
rFIXFc, FIX
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Up to 11 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Phoenix, Arizona • Sacramento, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 19, 2026, 4:43 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

NCT06379789
View directory record Official record
Conditions
Hemophilia B
Interventions
REGV131, LNP1265
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
2 Years and older · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2047
U.S. locations
16
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 4:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra

NCT02270918
View directory record Official record
Conditions
Thrombosis
Interventions
Kcentra, Apixaban, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Oct 19, 2026, 4:43 AM EDT
Terminated No phase listed Observational

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes

NCT02392156
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
rFVIIIFc, rFIXFc, non-Fc FVIII replacement products, non-Fc FIX replacement products
Biological · Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Los Angeles, California • East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 19, 2026, 4:43 AM EDT
Completed Phase 3 Interventional

Study Evaluating rFIX; BeneFIX in Severe Hemophilia B

NCT00037557
View directory record Official record
Conditions
Hemophilia B
Interventions
BeneFIX
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
Up to 5 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
6
States / cities
Aurora, Colorado • Detroit, Michigan • New Brunswick, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Oct 19, 2026, 4:43 AM EDT
Recruiting Phase 4 Interventional

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

NCT04647227
View directory record Official record
Conditions
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Interventions
coagulation factor VIIa [recombinant]-jncw
Drug
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
12 Years to 100 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 19, 2026, 4:43 AM EDT
Recruiting Phase 3 Interventional

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

NCT04563520
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab, FEIBA, rFVIIa
Drug
Lead sponsor
Emory University
Other
Eligibility
6 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 19, 2026, 4:43 AM EDT
Completed No phase listed Observational

An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding

NCT02319460
View directory record Official record
Conditions
Hemorrhage
Interventions
Kcentra®, Plasma
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
2,238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 19, 2026, 4:43 AM EDT
Terminated Phase 2 Interventional

Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B

NCT03307980
View directory record Official record
Conditions
Hemophilia B
Interventions
PF-06838435 (formerly SPK-9001)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
17
States / cities
Sacramento, California • Metairie, Louisiana • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 19, 2026, 4:43 AM EDT
Terminated Phase 3 Interventional

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

NCT04489537
View directory record Official record
Conditions
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Interventions
MarzAA
Biological
Lead sponsor
Catalyst Biosciences
Industry
Eligibility
12 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 19, 2026, 4:43 AM EDT
Completed Phase 1 Interventional

Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B

NCT00979238
View directory record Official record
Conditions
Hemophilia B
Interventions
Gene Transfer, scAAV2/8-LP1-hFIXco
Genetic · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
3
States / cities
Stanford, California • Memphis, Tennessee • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 19, 2026, 4:43 AM EDT
Completed No phase listed Observational

ATHN 11: Liver Transplantation Outcomes Study

NCT04055051
View directory record Official record
Conditions
Hemophilia A and B, Liver Transplantation
Interventions
Not listed
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Peoria, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 19, 2026, 4:43 AM EDT
Terminated Phase 3 Interventional

Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor

NCT04867837
View directory record Official record
Conditions
Acute Major Bleeding
Interventions
Octaplex
Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Torrance, California • Gainesville, Florida • West Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 19, 2026, 4:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation

NCT02047565
View directory record Official record
Conditions
Bleeding
Interventions
60mg edoxaban, 180mg edoxaban, 50 IU/kg Beriplex P/N, 25 IU/kg Beriplex P/N, 10 IU/kg Beriplex P/N
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 19, 2026, 4:43 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)

NCT06349473
View directory record Official record
Conditions
Healthy Participants, Hemophilia A, Hemophilia B, Factor VII Deficiency
Interventions
SR604, Placebo
Drug
Lead sponsor
Equilibra Bioscience LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
9
States / cities
Glendale, California • Los Angeles, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 19, 2026, 4:43 AM EDT
Recruiting No phase listed Observational

Treatment of Hemophilia A Patients With FVIII Inhibitors

NCT04023019
View directory record Official record
Conditions
Hemophilia A
Interventions
Nuwiq, Octanate, Wilate, Emicizumab, Recombinant factor VIIa (rFVIIa), Activated prothrombin complex concentrate (aPCC)
Biological
Lead sponsor
Emory University
Other
Eligibility
Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 19, 2026, 4:43 AM EDT
Not listed No phase listed Observational

Natural History Study of Factor IX Treatment and Complications

NCT02502409
View directory record Official record
Conditions
Factor IX Deficiency
Interventions
Standard care with blood and urine sample collection
Other
Lead sponsor
Skane University Hospital
Other
Eligibility
Not listed
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 19, 2026, 4:43 AM EDT
Completed No phase listed Observational

Comparative Outcomes of PCC and Recombinant Activated Factor VIIa in Trauma-Associated Massive Transfusion

NCT07290634
View directory record Official record
Conditions
Thromboembolus, Massive Blood Transfusion; Thrombocytopenia, Trauma
Interventions
Number of Participants with massive blood transfusion
Procedure
Lead sponsor
Zeliha Alicikus
Government
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 4:43 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B

NCT02618915
View directory record Official record
Conditions
Hemophilia B
Interventions
DTX101
Genetic
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 19, 2026, 4:43 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

NCT05662319
View directory record Official record
Conditions
Hemophilia
Interventions
Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
8
States / cities
Orange, California • Minneapolis, Minnesota • Hackensack, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 19, 2026, 4:43 AM EDT
Completed Phase 1 Interventional

Phase I/IIa Study of FIXFc in Hemophilia B Patients

NCT00716716
View directory record Official record
Conditions
Hemophilia B
Interventions
rFIXFc
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Chicago, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 19, 2026, 4:43 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B

NCT01425723
View directory record Official record
Conditions
Severe Hemophilia B
Interventions
rFIXFc
Biological
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 19, 2026, 4:43 AM EDT